Chronic Kidney Disease

An increased risk of emergency department visits for patients with kidney disease was found when patients were exposed to extreme heat.

This study found that the recent change to remove race from the calculation of estimated glomerular filtration rate (eGFR) may incorrectly label potential donors who are Black as having chronic kidney disease (CKD).

The esteemed panel concludes with their final thoughts on CKD therapies and management.

Drs Feldman, Pitt, and Agarwal describe the common CKD health disparities seen at their institutions and the steps they have taken to address them.

A retrospective observational study found that there was a decline in health care services for patients with chronic kidney disease (CKD) during the early months of the COVID-19 pandemic.

Dr Bertram Pitt explains the possibility of combining SGLT2 inhibitors and MRAs when treating CKD and CV, and Paul Sapia, MHA, discusses how payers balance cost of care with disease progression and health disparities.

Dr Jeffrey Feldman discusses finerenone trial data and the role that it and SGLT2 inhibitors have played in patients with CKD.

A recent report found that 56% of patients from The Netherlands who underwent a kidney transplant were able to work and functioned well while working.

Genomic testing can benefit patients with chronic kidney disease (CKD) as more causative genes are identified and evidence for clinical utility is discovered.

Dr Agarwal provides a deep dive into the use of nonsteroidal mineralocorticoid receptor antagonists in CKD therapy.

Dr Feldman concludes the treatment landscape overview by discussing glycemic control, SGLT2 inhibitors, and other important management techniques.

A recent study found that patients with chronic kidney disease and atrial fibrillation are increasingly using direct oral anticoagulants.

A retrospective cohort study found that a drop in events signaling renal function decline during the COVID-19 pandemic could be associated with a decrease in fine particulate matter concentration.

Sarah Wells Kocsis, MBA, coauthor of the Milken Institute report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management,” discusses how the health care system can better suit the needs of patients with chronic kidney disease (CKD).

Post-menopausal women who had dynapenic-abdominal obesity, determined by hand-grip strength and waist circumference, had a higher risk of chronic kidney disease (CKD) compared with controls.

Sarah Wells Kocsis, MBA, is co-author of the Milken Institute report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.” She spoke to The American Journal of Managed Care® about the findings of the report and how they can be incorporated into care for patients with chronic kidney disease (CKD).

Sarah Wells Kocsis, MBA, is co-author of the Milken Institute report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.” She spoke to The American Journal of Managed Care® about the findings of the report and how they can be incorporated into care for patients with chronic kidney disease (CKD).

Katherine R. Tuttle, MD, FASN, FACP, FNKF, a nephrologist from the University of Washington and Providence Health Care, discussed new consensus guidelines that call for the early use of sodium glucose cotransporter 2 (SGLT2) inhibitors, GLP-1 receptor agonists, and finerenone in the care of patients with both chronic kidney disease (CKD) and diabetes.

Sarah Wells Kocsis, MBA, is co-author of the Milken Institute report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.” She spoke to The American Journal of Managed Care® about the findings of the report and how they can be incorporated into care for patients with chronic kidney disease (CKD).

A recent study found that the largest Medicare Advantage plans pay large markups to large dialysis organizations, and these inflated payments could increase out-of-pocket expenses for patients.

Coverage from the 2022 Congress of the American Society for Preventive Cardiology (ASPC) in Louisville, Kentucky, featuring 3 experts on aspects of hypertension treatment: Keith C. Ferdinand, MD, of Tulane University School of Medicine; Kim Allan Williams, MD, of the University of Louisville; and George C. Bakris, MD, of the University of Chicago Medicine.

A new trial has found that patient management through remote means could reduce all-cause mortality and hospitalizations for heart failure (HF) in patients with renal impairment.

A recent modeling study found that allocating kidneys to patients receiving dialysis was a better use of the organs from a societal perspective compared with giving kidneys to those on a preemptive waiting list.

A retrospective cohort study found that frailty was prevalent in patients with chronic kidney disease (CKD) and that the adverse effects could include end stage kidney disease (ESKD) and mortality.

A recent study found that lipid dysregulation was predictive of the risk of chronic kidney disease (CKD) and occurred years before the onset of CKD.